Cited by 113Connective Tissue Growth Factor ResearchPancreatic and Hepatic Oncology ResearchCancer Cells and Metastasis

Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis

Open access
Haque, Inamul, Mehta, Smita, Majumder, Monami, Dhar, Kakali, De, Archana, McGregor, Douglas, Van Veldhuizen, Peter J, Banerjee, Sushanta K +1 more·2011·Molecular Cancer

Abstract

Background: Despite recent advances in outlining the mechanisms involved in pancreatic carcinogenesis, precise molecular pathways and cellular lineage specification remains incompletely understood. Results: We show here that Cyr61/CCN1 play a critical role in pancreatic carcinogenesis through the induction of EMT and stemness. Cyr61 mRNA and protein were detected in the early precursor lesions and their expression intensified with disease progression. Cyr61/CCN1 expression was also detected in different pancreatic cancer cell lines. The aggressive cell lines, in which the expressions of mesenchymal/stem cell molecular markers are predominant; exhibit more Cyr61/CCN1 expression. Cyr61 expression is exorbitantly higher in cancer stem/tumor initiating Panc-1-side-population (SP) cells. Upon Cyr61/CCN1 silencing, the aggressive behaviors are reduced by obliterating interlinking pathobiological events such as reversing the EMT, blocking the expression of stem-cell-like traits and inhibiting migration. In contrast, addition of Cyr61 protein in culture medium augments EMT and stemness features in relatively less aggressive BxPC3 pancreatic cancer cells. Using a xenograft model we demonstrated that cyr61/CCN1 silencing in Panc-1-SP cells reverses the stemness features and tumor initiating potency of these cells. Moreover, our results imply a miRNA-based mechanism for the regulation of aggressive behaviors of pancreatic cancer cells by Cyr61/CCN1. Conclusions: In conclusion, the discovery of the involvement of Cyr61/CCN1 in pancreatic carcinogenesis may represent an important marker for PDAC and suggests Cyr61/CCN1 can be a potential cancer therapeutic target.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-10-8

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Silencing of CCN1 expression decreased tumor growth in xenografts of prostate cancer cells and pancreatic cancer cells.

    “Consistently, silencing of CCN1 expression decreased tumor growth in xenografts of prostate cancer cells [74] and pancreatic cancer cells [144].”

    From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [144]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 50 · Cited by 113

Research works printed but not linked: 1

  1. Gregory PA Bracken CP Bert AG Goodall GJ MicroRNAs as regulators of epithelial-mesenchymal transition Cell Cycle 2008 7 3112 3118 18927505

Authors
Haque, I., Mehta, S., Majumder, M., Dhar, K., De, A., McGregor, D., Van Veldhuizen, P. J., Banerjee, S. K., & Banerjee, S.
Affiliations
  • Kansas City VA Medical Center (US)
  • University of Kansas Medical Center (US)
Corresponding author
  • Banerjee, Sushanta K
  • Banerjee, Snigdha
Venue
Molecular Cancer
Published
2011-01-13
Volume
10
Issue
1
Pages
8-8
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2126649494
Cited by
113
References
50
Citations by year
2026: 3 · 2025: 9 · 2024: 5 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 11 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 12 · 2015: 8 · 2014: 7 · 2013: 8 · 2012: 13
FWCI
4.54
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
U.S. Department of Veterans Affairs
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
epithelial-mesenchymal transition, cancer stemness, pancreatic cancer, pancreatic ductal adenocarcinoma, cancer stem cells, side population cells, cell migration, microRNA regulation, tumor aggressiveness, therapeutic target
MeSH terms
Adenocarcinoma, Animals, Cell Movement, Humans, Male, Mice, Nude, Neoplasm Transplantation, Pancreatic Neoplasms, Biomarkers, Tumor, Neoplastic Stem Cells, Up-Regulation, Paracrine Communication, Gene Expression Profiling, RNA Interference, MicroRNAs, Mice, Cysteine-Rich Protein 61, Epithelial-Mesenchymal Transition, Side-Population Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review